lestaurtinib has been researched along with Body Weight in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dong, L; He, HL; Lu, XM; Qiu, HB; Yang, Y | 1 |
Chang, H; Dionne, CA; Klein-Szanto, A; Miknyoczki, SJ; Ruggeri, BA | 1 |
2 other study(ies) available for lestaurtinib and Body Weight
Article | Year |
---|---|
Modulation of FLT3 signaling targets conventional dendritic cells to attenuate acute lung injury.
Topics: Acute Lung Injury; Animals; Body Weight; Carbazoles; Cytokines; Dendritic Cells; fms-Like Tyrosine Kinase 3; Furans; GATA3 Transcription Factor; Gene Expression; Lipopolysaccharides; Lung; Lymphocyte Count; Male; Mice; Mice, Inbred C57BL; Organ Size; Peroxidase; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; T-Box Domain Proteins | 2012 |
The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Carbazoles; Drug Screening Assays, Antitumor; Female; Furans; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor, trkA; Time Factors; Trachea; Treatment Outcome; Tumor Cells, Cultured | 1999 |